Abstract
Adolescents infected with human immunodeficiency virus (HIV) represent a heterogeneous group of pubertal children and young adults. Antiretroviral therapy (ART) in adolescents is complex and depends on multiple factors. The continued use of higher (weight- or surface-based) pediatric doses can result in potentially toxic drug exposure, whereas early introduction of lower adult doses can lead to the development of drug resistance and virologic failure. The physiological and psychosocial changes during puberty create strong grounds for an individualized therapeutic approach in HIV-infected adolescents.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Acquired Immunodeficiency Syndrome / diagnosis
-
Acquired Immunodeficiency Syndrome / drug therapy
-
Adolescent
-
Age Factors
-
Anti-HIV Agents / administration & dosage*
-
Anti-HIV Agents / adverse effects
-
Anti-Retroviral Agents
-
Antiretroviral Therapy, Highly Active / adverse effects
-
Antiretroviral Therapy, Highly Active / methods
-
Clinical Trials as Topic
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Female
-
Global Health
-
HIV Infections / diagnosis
-
HIV Infections / drug therapy*
-
HIV Seropositivity
-
Humans
-
Male
-
Maximum Tolerated Dose
-
Needs Assessment
-
Patient Care Planning*
-
Practice Guidelines as Topic*
-
Prognosis
-
Reverse Transcriptase Inhibitors / administration & dosage*
-
Reverse Transcriptase Inhibitors / adverse effects
-
Risk Assessment
-
Severity of Illness Index
-
Treatment Outcome
-
World Health Organization
Substances
-
Anti-HIV Agents
-
Anti-Retroviral Agents
-
Reverse Transcriptase Inhibitors